• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Novocure Ltd Ord Sh (NQ: NVCR )

    19.02 +0.37 (+1.98%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,236,980
    Open 19.36
    Bid (Size) 17.90 (1)
    Ask (Size) 19.02 (1)
    Prev. Close 18.65
    Today's Range 17.85 - 19.36
    52wk Range 10.87 - 35.10
    Shares Outstanding 103,647,871
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Beyond The Numbers: 4 Analysts Discuss NovoCure Stock
    Via Benzinga
    NovoCure (NVCR) Q2 2024 Earnings Call Transcript
    NVCR earnings call for the period ending June 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial

    Performance

    YTD
    +32.08%
    +32.08%
    1 Month
    +7.88%
    +7.88%
    3 Month
    +48.59%
    +48.59%
    6 Month
    +22.79%
    +22.79%
    1 Year
    -42.92%
    -42.92%

    More News

    Read More
    NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q2 2024
    Via InvestorPlace
    Novocure Reports Second Quarter 2024 Financial Results
    From Novocure
    Via Business Wire
    Breaking Down NovoCure: 4 Analysts Share Their Views
    Via Benzinga
    Novocure to Report Second Quarter 2024 Financial Results
    From Novocure
    Via Business Wire
    A Closer Look at 7 Analyst Recommendations For NovoCure
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    METIS Phase 3 Clinical Trial Met Primary Endpoint Significantly Delaying Time to Intracranial Progression with Improved Quality of Life Deterioration-Free Survival
    From Novocure
    Via Business Wire
    Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Unveiling 8 Analyst Insights On NovoCure
    Via Benzinga
    Why NovoCure Stock Soared 18.3% This Week
    Via The Motley Fool
    Why Novocure Stock Is Jumping Today
    Via The Motley Fool
    Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Double-Up Delights: 7 Stocks Poised to Soar 100% by 2025
    Via InvestorPlace
    NovoCure (NVCR) Q1 2024 Earnings Call Transcript
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    NVCR Stock Earnings: NovoCure Beats EPS, Beats Revenue for Q1 2024
    Via InvestorPlace
    Novocure Secures New $400 Million Multi-Tranche Non-Dilutive Debt Financing from Pharmakon
    From Novocure
    Via Business Wire
    Novocure Reports First Quarter 2024 Financial Results
    From Novocure
    Via Business Wire
    Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
    From Novocure
    Via Business Wire
    Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
    From Novocure
    Via Business Wire
    10 Health Care Stocks Whale Activity In Today's Session
    Via Benzinga
    Novocure to Report First Quarter 2024 Financial Results
    From Novocure
    Via Business Wire
    Novocure Stock Soars, Its Lung Cancer Electric Field Treatment Slows Progression To Brain, Data Shows
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.